PTO/SB/08A (08-03) Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

11/15/2007

Considered

Substitute for form 1449/PTO

Sheet 1

Examine

Signature

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT (Use as many sheets as necessary) of 1

Complete if Known Application Number 10/809.089 Filing Date 03/25/04 First Named Inventor Andrew R. Marks Art Unit 1624 Examiner Name to be assigned Attorney Docket Number 5199-144

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (Finner)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/B.P.		US- 5,416,066	05-16-1995	Kaneko, et al.	
		US-			
	_	US-			-
		US-			
		US-			
		US-	+ -		
		US-	1		-
	-	US-			
		US-			
	-	US-			
	\vdash	US-			
	-	US-			
	-	US-			

			FORE	IGN PATENT DOCU	IMENTS				
Examiner Initials*		Cite No.1			Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
			Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	,,	Or Relevant Figures Appear	Τ°		
/E	3.P./		WO92/12148	07-23-1992	Kaneko, et al. Engli	sh Abstract O	nly		
	*****		JP4230001	00-19-1992	Kaneko, et al.		-		
			10100001	00 10 1002			-		
			3P10045700		Hsuda, et al.		-		
							┢		
							┝		
	- 1						_		

"EXAMINER: Initial if reference considered, whether or not clastion is in conformance with MPEP 600. Draw lime through platition if not in conformance and not considered, include copy of this form with next communication to applicant." Applicant's unique clastion designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usids.og.gv or MPEP 9010.—"Enter Office that issued the document, by the two-letter code (MPO Standard ST.3)." For Japanese patent document, be indication of the year of the reging of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under MPO Standard ST in for postate." Applicant is to place a check make here of English inspages. See Kinds Codes of Standard ST.3). For Translation is attached

Irransiation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the IUSPTC) to process an application. Confidentiality is governed by 35 U.SC. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, repeating, and submitting the completed application from the bus USPTC. Three Way depending out on the information are information and in advantage of the information and in advantage of the information of the information are information and in advantage of the information are information of the informatio TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

/Benjamin J. Packard/

NOV 2 6 2004 5

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. DMB 0551-0031
U.S. Patent and Trademark Office; U.S. OEPARTMENT OF COMMERCE

Uol	der the Paperwork Rec	luction A	ct of 1995, no persons ar	e required to respond to a collection	n of information unless it contains a valid OMB control number.
OEMA	te for form 1449/PTO				Complete if Known
	10 10 11 14-51 10			Application Number	10/809,089
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04
STA	STATEMENT BY APPLICANT			First Named Inventor	Andrew R. Marks
	(Use as many she			Art Unit	1624
	(Ose as many sne	ets as n	ecessary)	Examiner Name	to be assigned
Sheet	1	of	16	Attomey Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Alvarez et al., Late post-myocardial infarction induces a tetrodotoxin-resistant Na+ current in rat cardiomyocytes.	
		J. Mol. Cell Cardiol., 32: 1169-1179, 2000	
		Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation / flutter in a canine sterile pericarditis model.	
		J. Cardiovasc. Electrophysiol., 14: 880-884, 2003	
		Antos et al., Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A.	
		Circ. Res., 89: 997-1004, 2001	
		Barbone et al., Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure:	
		a primary role of mechanical unloading underlying reverse remodeling.	
		Circulation, 104: 670-675, 2001	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature	750 njamin 6: 1 dokara	Considered	11775/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

The ordinary control control of the property o

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
/ Substitute for form 1446F-10	Application Number	10/809,089
INFORMATION DISCLOSURE	Filing Date	03/25/04
STATEMENT BY APPLICANT	First Named Inventor	Andrew R. Marks
(Use as many sheets as necessary)	Art Unit	1624
(Ose as many sneets as necessary)	Examiner Name	to be assigned
Sheet 2 of 16	Attorney Docket Number	5199-144

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Bennett and Pentecost, The pattern of onset and spontaneous cessation of atrial fibrillation in man.	
		Circulation, 41: 981-988, 1970	
		Bennett et al., Identification and characterization of the murine FK506 binding protein (FKBP) 12.6 gene.	
		Mamm. Genome, 9: 1069-1071, 1998	
		Beuckelmann et al., Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure.	
		Circ., 85: 1046-1055, 1992	
		Brillantes et al., Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein.	
		Cell, 77: 513-523, 1994	
		Bristow et al., Decreased catecholamine sensitivity and beta-adrenergic -receptor density in failing human hearts.	
		N. Engl. J. Med., 307: 205-211, 1982	

Examiner Signature	/Benjamin J. Packard/	Date Considered	11/15/2007
*EXAMINER: II	nitial if reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through o	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

considered, mouse copy of this form with next communication to application. It Applicants using uside the design of the property of the proper Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

		luction A	ct of 1995, no persons a	re required to respond to a collection	n of information unless it contains a valid OMB control number. Complete if Known
Substitu	te for form 1449/PTO			Application Number	10/809,089
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many she			Art Unit	1624
	(use as many sne	ets as r	ecessary)	Examiner Name	to be assigned
Sheet	3	of	16	Attorney Docket Number	5199-144

***		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cily and/or country where published.	Τ²
		Burashnikov and Antzelevitch, Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early	
		afterdepolarization-induced triggered activity.	
		Circulation, 107: 2355-2360, 2003	
		Cameron et al., FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this	
		FK506-like domain.	
		J. Biol. Chem., 272: 27582-27588, 1997	
		Chen et al., Mechanism of TGFbeta receptor inhibition by FKBP12.	
		EMBO J., 16: 3866-3876, 1997	
		Chidsey et al., Augmentation of plasma norepinephrine response to exercise in patients with congestive heart failure.	
		N. Engl. J. Med., 267: 650, 1962	

Examiner Signature	/Benjamin J. Packard/	Date Considered	11/15/2007
*EXAMINER: In	nitial if reference considered, whether or not citation is in conformance with MPEP 60	9. Drawline through o	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

considered. Induced copy of this form with next communication to application. It applicants using classification designation comments (policinal). Supplicated its to place a check mark here if English singuiage Translation is attached. This collection of information is required by 30° FFF 18. The information is required to obtain or makes a benefit by the public which is liked by the USPTO This collection of information is required by 30° FFFF 18. The information is required to obtain or which a benefit by the public which is liked by the USPTO. The collection of the USPTO. The well vary depending upon the information allowed included case. Any other including stateming, prapagaring, and submitting the completed specification from the USPTO. There will vary depending upon the information Officer, U.S. Patient and Tademark Officer, 0.0 Ross 1456, Meandard, V.A. 2231-1456, D.O. NOT SSEMD FESS OR COMPLETED FORMS TO THIS ADDRESS. SENTO TO Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449PTO	
INFORMATION DISCLOSURE Filing Date 03/25/04	
STATEMENT BY APPLICANT First Named Inventor Andrew R. Marks	
(Use as many sheets as necessary)	
Examiner Name to be assigned	
Sheet 4 of 16 Attorney Docket Number 5199-144	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Chugh et al., Epidemiology and natural history of atrial fibrillation: clinical implications.	
		J. Am. Coll. Cardiol., 37: 371-378, 2001	
		Cranefield, P.F., Action potentials, afterpotentials, and arrhythmias.	
		Circ. Res., 41: 415-423, 1977	
		Daoud et al., Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans.	
		Circulation, 96: 1542-1550, 1997	
		Dun et al., Chronic atrial fibrillation does not further decrease outward currents. It increases them.	
		Am. J. Physiol. Heart Circ. Physiol., 285: H1378-1384, 2003	
		Eichhorn and Bristow, Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure.	
		Circulation, 94: 2285-2296, 1996	
	1	I .	

Examiner Signature	/Benjamin J. Packard/	Date Considered	11/15/2007
'EXAMINER: II	itial if reference considered, whether or not citation is in conformance with MPEP 60	9. Drawline through c	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached.

I Applicant's unique citation designation number (optional). A Applicant is to place a dress, make rise if building individual instruction is statistical. The collection of information is required by 37 CFR 18.0 This information is required to data or retain a benefit by the public which is to first children in the control of the cont

	der the Paperwork Re te for form 1449/PTO		ct of 1995, no persons a	re required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substilu	te for form 1448/F FO			Application Number	10/809,089
INF	ORMATION	N DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many sh			Art Unit	1624
	(Use as many sn	eers as r	iecessary)	Examiner Name	to be assigned
Sheet	5	of	16	Attorney Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Elvan et al., Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs: electrophysiological remodeling.	
		Circulation, 94: 2953-2960, 1996	
		Fabiato, A., Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum.	
		Am. J. Physiol., 245: C1-C14, 1983	
		Falk, R.H., Atrial fibrillation.	
		N. Engl. J. Med., 344: 1067-1078, 2001	
		Fozzard, H.A., Afterdepolarizations and triggered activity.	
		Basic Res. Cardiol., 87: 105-113, 1992	
		Gaspo et al., Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model.	
		Circulation, 96: 4027-4035, 1997	

Examiner Signature	/Benjamin J. Packard/	Date Considered	11/15/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

considered, include copy of the form with next communication to appeticate the pulses of check may have \$1.40 feet and included the communication and pulses of the communication and the communicatio Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	the Paperwork Red for form 1449/PTO	uction Ad	ct of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitute	or 10m1 1449/F1O			Application Number	10/809,089
INFO	RMATION	DIS	CLOSURE	Filing Date	03/25/04
STAT	EMENT B	ΥA	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many she	ote oe n	accessed.	Art Unit	1624
	(Ose as many sne	cus da II	occasary)	Examiner Name	to be assigned
Sheet 6		of	16	Attorney Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), tille of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Gillo et al., Calcium entry during induced differentiation in murine erythroleukemia cells.	
		Blood, 81: 783-792, 1993	
		Goette et al., Electrical remodeling in atrial fibrillation: time course and mechanisms.	
		Circulation, 94: 2968-2974, 1996	
		Gomez et al., Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure.	
		Science, 276: 800-806, 1997	
		Gwathmey et al., Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.	
		Circ. Res., 61: 70-76, 1987	
		Hain et al., Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle.	
		J. Biol. Chem., 270: 2074-2081, 1995	

Examiner Signature	/Benjamin J. Packard/	Date Considered	11/15/2007
*EXAMINER: II	itial if reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through o	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

¹ Applicants unique cetation designation number (optional). Applicant is to place a check mark here it engine larguage frantiation is attacked. This collection of information is required by 37 CET 19.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CET 1.14. This collection is estimated to take it hours to complete, including generating, preparing, and submitting the completed applications must be the USPTO. This well vary deprinding upone the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this brother, should be sent to the Chief Information Chief. U.S. Patient and Trademark Office, 20. Dots 1456, Assardin, 34 v. 22131-1450. ON OTS SEAD FEES OR COMPLETED PICHANT OT 1148 J.O.CHESS. SEAD TO. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

$\overline{}$	der the Paperwork Re		ct of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitu	te for form 1449/P1O			Application Number	10/809,089
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many si			Art Unit	1624
	(Use as many si	reets as r	eccssary)	Examiner Name	to be assigned
Sheet	7	of	16	Attorney Docket Number	5199-144

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	т-
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Hara et al., Steady-state and nonsteady-state action potentials in fibrillating canine atrium: abnormal rate adaptation and its possible mechanisms.	
		Cardiovasc. Res., 42: 455-469, 1999	
		Jayaraman et al., FK506 binding protein associated with the calcium release channel (ryanodine receptor).	
		J. Biol. Chem., 267: 9474-9477, 1992	
		Jayaraman et al., Regulation of the inositol 1,4,5-trisphosphate receptor by tyrosine phosphorylation.	
		Science, 272: 1492-1494, 1996	
		Kaftan et al., Effects of rapamycin on ryanodine receptor / Ca (2+)-release channels from cardiac muscle.	
		Circ. Res., 78: 990-997, 1996	
		Kneller et al., Remodeling of Ca2+ - handling by atrial tachycardia: evidence for a role in loss of rate-adaptation.	
		Cardiovasc. Res., 54: 416-426, 2002	

Examiner	/Benjamin J. Packard/	Date	11/15/2007	\neg
Signature		Considered	11/15/2007	- 1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant in the price of the control of the c Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	der the Paperwork Rule for form 1449/PTC		ct of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitu	ite for form 1449/FTC	,		Application Number	10/809,089
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/25/04
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many s			Art Unit	1624
	(Use as many s	neets as n	ecessary)	Examiner Name	to be assigned
Sheet	8	of	16	Attorney Docket Number	5199-144

_	1 60	NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Kohno et al., A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure.	
		Am. J. Physiol. Heart Circ. Physiol., 14:14, 2002	
		Kumagai et al., Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation / flutter in a canine sterile pericarditis model.	
		J. Cardiovasc. Electrophysiol., 14: 880-884, 2003	
		Laitinen et al., Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia.	
		Circulation, 103: 485-490, 2001	
		Leenhardt et al., Catecholaminergic polymorphic ventricular.tachycardia in children: a 7-year follow-up of 21 patients.	
		Circulation, 91: 1512-1519, 1995	
		Leistad et al., Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644.	
		Circulation, 93: 1747-1754, 1996	

Examiner	/Benjamin J. Packard/	Date	11/15/2007	
Signature		Considered	1	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

¹ Applicants unique citation designation number (optional). A Applicant is to place a check mark nere it engine inaquage (faristation is attached. by the control process) an application. Confidentially is governed by 30 LSC. 122 and 1570. The information is required to obtain or relating a benefit by the public which is to file (and to process) an application. Confidentially is governed by 30 LSC. 122 and 1570. The confidential is governed by 30 LSC. 122 and 1570. The way of the confidence is the confidential in the confidence is the confidence is the confidence in the confidence is the confidence i

_	ite for form 1449/PTO		a di 1995, ilo persona ai	e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
3005000	16 10 10 11 14431 10			Application Number	10/809,089	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/25/04	
STATEMENT BY APPLICANT				First Named Inventor	Andrew R. Marks	
				Art Unit	1624	
(Use as many sheets as necessary)				Examiner Name	to be assigned	
Sheet	9	of	16	Attorney Docket Number	5199-144	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Levy et al., Long-term trends in the incidence of and survival with heart failure.	
		N. Engl. J. Med., 347: 1397-1402, 2002	
		Marban et al., Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle.	
		J. Clin. Invest., 78: 1185-1192, 1986	
		Marks, A.R., Cellular functions of immunophilins.	
		Physiol. Rev., 76: 631-649, 1996	
		Marks, A.R., Cardiac intracellular calcium release channels: role in heart failure.	
		Circ. Res., 87: 8-11, 2000	
		Marks et al., Progression of heart failure: is protein kinase a hyperphosphorylation of the ryanodine receptor a contributing factor?	
		Circulation, 105: 272-275, 2002	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature	•	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant. In Applicant's using uside ordinary united processing the product of the processing and processing an application. This collection of information is required by 37 CFR 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 US 1. C12 and 37 CFR 11.4. This collection is estimated to task 2-brus to connecte, including gathering, preparing, and submitting the completed application form to be USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or augusterions for reducing the burden, should be set to the Cheft information Officer, U.S. Patient and Trademan Cffice, P.O. Box 1450, Alexandris, V.A. 2231-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

$\overline{}$	der the Paperwork Red te for form 1449/PTO	uction A	ct of 1995, no persons a	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitu	te for form 1449/P1O			Application Number	10/809,089
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(the sement shows			Art Unit	1624
(Use as many sheets as necessary)				Examiner Name	to be assigned
Sheet	10	of	16	Attorney Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Marx et al., Coupled gating between individual skeletal muscle Ca2+ release channels (ryanodine receptors).	
		Science, 281: 818-821, 1998	
		Marx et al., PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.	
		Cell, 101: 365-376, 2000	
		Mohler et al., Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death.	
		Nature, 421: 634-639, 2003	
		Morillo et al., Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation.	
		Circulation, 91: 1588-1595, 1995	
		Nabauer et al., Regulation of calcium release is gated by calcium current, not gating charge, in cardiac myocytes.	
		Science, 244: 800-803, 1989	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant. It is placed a check mark here if English language Translation is attached.

Applicant's unique cladiation designation number (optional). Speptional is to place a check mark here if English language Translation is attached.

This codection of information is required by 3°C (Fig. 1). The information is required to obtain or retain a benefit by the public which is like only in the USPTO flat of the public or the Communication of the Co

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known		
Substitute to Horiti 14439 10	Application Number	10/809,089		
INFORMATION DISCLO	SURE Filing Date	03/25/04		
STATEMENT BY APPLI	CANT First Named Inventor	Andrew R. Marks		
(Use as many sheets as necessary)	Art Unit	1624		
(Use as many sneets as necessary)	Examiner Name	to be assigned		
Sheet 11 of 16	Attorney Docket Number	5199-144		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Ono et al., Altered interaction of FKBP12.6 with ryanodine receptor as a cause of abnormal Ca2+ release in heart failure.	
		Cardiovasc. Res., 48: 323-331, 2000	
		Priori et al., Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.	
		Circulation, 106: 69-74, 2002	
		Priori et al., Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia.	
		Circulation, 103: 196-200, 2001	
		Ramirez et al., Mathematical analysis of canine atrial action potentials: rate, regional factors, and electrical remodeling.	
		Am. J. Physiol. Heart Circ. Physiol., 279: H1767-1785, 2000	
		Reiken et al., Beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure.	
		Circulation, 104: 2843-2848, 2001	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature	·	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

consorron. Include copy of this form with next communication to application. It applicant is not performed to a post of the property of the pr Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Subatitu	te for form 1449/PTO			Complete if Known		
Substitu	te to total 1445/FTO			Application Number	10/809,089	
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks	
				Art Unit	1624	
	(Use as many she	eets as n	ecessary)	Examiner Name	to be assigned	
Sheet	12	of	16	Attorney Docket Number	5199-144	

		NON PATENT LITERATURE DOCUMENTS .	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Reiken et al., Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure.	
		Circulation, 107: 2459-2466, 2003	
		Reiken et al., PKA phosphorylation dissociates FKBP12 from the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation	
		in heart failure.	
		J. Cell Biol., 160: 919-928, 2003	
		Rensma et al., Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs.	
		Circ. Res., 62: 395-410, 1988	
		Semsarian et al., The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model.	
		J. Clin. Invest., 109: 1013-1020, 2002	

Examiner Signature	/Benjamin J. Packard/	Date Considered	11/15/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not						

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to piace a check mark here if English language Translation is attached.

¹ Applicant's unique cliation designation number (optional). Applicant is to place a desict what keet it English instruguing intrahealisms assistant as the place and the place and the place of the place which is to file assistant, and it is not provided by 30° CFR 1.08. The information is required to obtain or retain a benefit by the poble which is to file assistant, or to provide a provided by 30° CFR 1.08. The information is required to obtain or retain a benefit by the poble which is to file deposition. The place of the place of

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO				e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitu	10 10 10 III 1445F 10			Application Number	10/809,089	
INFO	DRMATION	DIS	CLOSURE	Filing Date	03/25/04	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	Andrew R. Marks	
	(lles es mesu abou abou	a t o on a		Art Unit	1624	
(Use as many sheets as necessary)				Examiner Name	to be assigned	
Sheet	13	of	16	Attorney Docket Number	5199-144	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Song and Belardinelli, ATP promotes development of afterdepolarizations and triggered activity in cardiac myocytes.	
		Am. J. Physiol., 267: H2005-2011, 1994	
		Sun et al., Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia.	
		Circulation, 98: 719-727, 1998	
		Swan et al., Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts.	
		J. Am. Coll. Cardiol., 34: 2035-2042, 1999	
		Tieleman et al., Verapamil reduces tachycardia-induced electrical remodeling of the atrial.	
		Circulation, 95: 1945-1953, 1997	
		Timmermans et al., Immediate reinitiation of atrial fibrillation following internal atrial defibrillation.	
		J. Cardiovasc. Electrophysiol., 9: 122-128, 1998	

Examiner	/Benjamin J. Packard/	Date	11/15/2007	\neg
Signature		Considered		- 1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Agolican's unique claidron designation number (optional). A Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.9. The information is required to obtain or retain a benefit by the public which is to tife (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR 1.1.4. This collection is estimated to take 2 hours to complete, including adhering, preparing, and submitting the completed application from the the USPTO. Time will very depending upon the endothedial sease. Any comments on the operation of the complete application of the USPTO. Time will very depending upon the endothedial sease. Any comments on the Trademark Office, P.O. Box 1459. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioned For Patents, P.O. Box 1459. Alexandria, VA 22313-1450.

(2.200	te for form 1449/PTO			Complete if Known		
Substitu	18 101 101111 1449/F1O			Application Number	10/809,089	
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04	
STATEMENT BY APPLICANT				First Named Inventor	Andrew R. Marks	
				Art Unit	1624	
(Use as many sheets as necessary)				Examiner Name	to be assigned	
Sheet	14	of	16	Attorney Docket Number	5199-144	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Valdivia et al., Rapid adaptation of cardiac ryanodine receptors: modulation by Mg2+ and phosphorylation.	
		Science, 267: 1997-2000, 1995	
		Wang et al., Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs.	
		Am. J. Physiol., 271: H148-158, 1996	
		Wehrens et al., FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death.	
		Cell, 113: 829-840, 2003	
		Wellens et al., Atrioverter: an implantable device for the treatment of atrial fibrillation.	
		Circulation, 98: 1651-1656, 1998	
		Wijffel et al., Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats.	
		Circulation, 92:1954-1968, 1995	

Examiner	D : : ! D ! !!	Date	11/15/2007			
Signature	/Benjamin J. Packard/	Considered	1			
			N-8 M I I			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not						

considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant. I Applicants in size decided capital continues of the property of Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	der the Paperwork Red te for form 1449/PTO	uction A	ct of 1995, no persons ar	e required to respond to a collection	of Information unless it contains a valid OMB control number. Complete if Known
Substitu	te tor torm 1445/F1O			Application Number	10/809,089
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many she	oto oe a		Art Unit	1624
(Use as many sheets as necessary)			ecessary	Examiner Name	to be assigned
Sheet	15	of	16	Attorney Docket Number	5199-144

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Wit and Rosen, Pathophysiologic mechanisms of cardiac arrhythmias.	
		Am. Heart J., 106: 798-811, 1983	
		Yamamoto et al., Abnormal Ca2+ release from cardiac sarcoplasmic reticulum in tachycardia-induced heart failure.	
		Cardiovasc. Res., 44: 146-155, 1999	
		Yano et al., Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca2+ leak through ryanodine receptor in heart failure.	
		Circulation, 102: 2131-2136, 2000	
		Yano et al., FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure.	
		Circulation, 107: 477-484, 2003	
		Yu et al., Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.	
		Circulation, 97: 2331-2337, 1998	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature		Considered	117.10.2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Applicant's unique clation designation number (optional). 2 Applicant's late a check mark here if English language Translation is attached.
This collection of information is required by 37 CPR 1.93. The information is required by 37 CPR 1.94. The information is required by 36 LSC. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to complete, including the process an amplication. Confidentiality is governed by 35 U.SC. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to complete, including approximation to complete this comment is guideling, preparation of time by complete application from the text SEPTO. Time will vary depending upon the individual case. Any comments on the announce of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Child Information Officer, U.S. Patent and Trademark Officer, P.O. Box 1450, Advanding, AZ 2313-4450, D.N ONT SERND FEES DIC COMPLETED FORMs TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	der the Paperwork Red te for form 1449/PTO	luction A	ct of 1995, no persons a	re required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitu	te for form 1449/PTO			Application Number	10/809,089
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many she	.		Art Unit	1624
	(Use as many sm	ners as n	ecessary)	Examiner Name	to be assigned
Sheet	16	of	16	Attorney Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the letm (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Yue et al., lonic remodeling underlying action potential changes in a canine model of atrial fibrillation.	
		Circ. Res., 81: 512-525, 1997	
-			

Examiner	/Benjamin J. Packard/	Date	11/15/2007	
Signature		Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

^{*} Applicants is unique cristion designation number (policional). Applicant is to place a crisce, man new 8 Emplits illustragate (ransiation is automatic). This collection of Internation is required by 27 CFR 193. The internation is required to obtain our retain a benefit by the public which is to file (and vy his USPT) to process) an application. Confidentiality is governed in the internation is required to obtain our retain a benefit by the public which is to file (and vy his USPT) to process) an application. Confidentiality is governed and public of the internation of the in